Prediction of spontaneous preterm birth using cervicovaginal fluid quantitative fetal fibronectin in asymptomatic women with cervical surgery is valid.
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Condensation
Prediction of spontaneous preterm birth using cervicovaginal fluid quantitative fetal fibronectin in asymptomatic women with cervical surgery is valid.
Short version of title
Quantitative fetal fibronectin testing after cervical surgery M A N U S C R I P T Results: The rate of spontaneous preterm birth <34 weeks' in the cervical surgery group was 3% compared with 9% in previous spontaneous preterm birth group.
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Receiver operating characteristic curves comparing quantitative fetal fibronectin for M A N U S C R I P T FFN is an adhesive glycoprotein normally found in the fetal membranes and decidua.
As the gestational sac implants and attaches to the interior of the uterus in early pregnancy, presence of FFN in the CVF is regarded as 'physiological'. 4 
It is well established that women who have undergone invasive cervical surgery (e.g. laser loop excision, or cone biopsy for premalignant changes) are at more than double the risk of sPTB than the background population, although this may differ with procedure and depth of biopsy. 10 Although used increasingly in clinical practice, the ability of qFFN to predict premature birth in women with previous cervical surgery, compared with women at high risk by virtue of their obstetric history, has never been described and routine FFN testing in asymptomatic women with prior cervical surgery is not recommended by NICE. 11 It is possible that the aetiology underlying sPTB may be different in women with previous cervical surgery who have mechanically shortened cervices, compared with women with a previous sPTB, in whom decidual disruption results in activation of inflammatory pathways.
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The predictive power of qFFN may be different in these two groups.
We hypothesized that qFFN could be used to predict subsequent PTB in women with previous cervical surgery. The primary aim was to compare the predictive value of qFFN in a cohort of primiparous women with previous invasive cervical surgery, compared to women with prior sPTB.
Materials and Methods
This was a pre-defined prospective masked secondary analysis of a larger observational study of CVF qFFN concentration (ng/ml) in asymptomatic women using commercially available rapid bedside FFN testing (Hologic™). 9, 13 Samples M A N U S C R I P T cm, frank bleeding, or rupture of membranes (on speculum examination) were excluded from the study because of interference with qFFN measurement (Figure 1 ).
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Samples that were blood stained, or from women who had undergone sexual intercourse or vaginal examination within the past 24 hours were excluded (due to known interference with qFFN measurement 14 ) , and the next eligible qFFN test was used if one was available within the gestational age limit of 22-27 +6 weeks.
Categorical TLIQ data (positive/negative) were provided to clinicians, but quantitative 10Q results remained masked (a random result code was generated by the analyzer) until after delivery. Thresholds of 10, 50, 200, and 500 ng/mL were predefined before analysis, based on the literature 5, 8 . A sterile speculum examination was performed, and a polyester swab was inserted for 10 seconds into were trained in the use of the FFN analyser. After FFN swabs were taken, at the same appointment, CL was measured (mm) using TVS performed by trained staff; the mean of three values was used in this analysis. All sonographers were formally trained by the institution's governance requirements, which included formal assessment prior to accreditation. The mean value was taken to be consistent with our previous evidence. 9 Cervical length measurements were taken and recorded prior to any FFN assay.
From the cohort of asymptomatic high risk women who met the criteria for analysis (n= 1294), 2 groups of women were selected; primiparous women (no previous pregnancy lasting >14 weeks' duration) with singleton pregnancies at 22-27 +6 weeks of gestation who had undergone invasive cervical surgery (e.g. LLETZ, cone/loop biopsy) (n= 473) prior to their index pregnancy, and women with singleton pregnancies at 22-27 +6 weeks of gestation, with prior sPTB <37 weeks', premature rupture of membranes (PPROM) or miscarriage >14 weeks' gestation, who had never undergone any cervical surgery (n= 821). Where multiple visits had occurred, the first eligible visit in the gestational age bracket was used. A formal power calculation was not performed as this was a planned subgroup analysis of a previously powered study. We chose not to include multiparous women without
prior sPTB into the cervical surgery group to limit the number of variables affecting the risk of PTB.
Descriptive characteristics were calculated for baseline demographics in both groups. Logistic regression and interaction tests were used to assess whether the meaning of the FFN test results varied according to the women's risk group. Calculations were carried out in Stata version 11.2 (StataCorp, College
Station, Texas). The performance of qFFN as a predictor of sPTB was tested for different gestational age limits (prior to 34 weeks (primary outcome), 30 and 37 weeks) and predictive statistics for sPTB were calculated and compared between the previous cervical surgery and previous PTB groups; ROC areas were calculated and compared, 15 and sensitivity, specificity, predictive values, likelihood ratios and relative risk were assessed at pre-specified endpoints: 10, 50, 200, 500 ng/mL. The utility of CL measurement following stratification by qFFN category was explored, as well as the utility of qFFN following stratification by the presence and absence of a short cervix (<25 mm). A composite score was developed by using logistic regression for the continuous variables of CL and the log of qFFN concentration to predict prematurity before 34 weeks. The composite score was compared with 2 continuous measurements of qFFN and CL using ROC curve analysis 15 . Iatrogenic PTB prior to the gestational age outcome under consideration were excluded from statistical analysis ( Figure 1 ).
Results
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A total of 473 women with previous cervical surgery were eligible for analysis and comparison was made with 821 women with one previous sPTB. The mean gestational age of testing was 23 +3 weeks (SD ±1.90). Demographics for study participants, and the nature of cervical surgery are illustrated in Figure 2 . The proportion of women of African and Afro-Caribbean origin was lower in the cervical surgery group than previous sPTB.
Concentrations of qFFN were obtained for all women with the use of the 10Q test.
There were no adverse events related to the test. Overall, the rate of sPTB <34
weeks' after iatrogenic deliveries were excluded in the cervical surgery group was 14/468 (3%) compared with 71/809 (9%) in the previous sPTB group. The number of women and proportion of preterm deliveries assigned to each of the pre-specified qFFN categories is shown in Table 2 . 82% of women in the cervical surgery group and 61% in the sPTB group had CVF qFFN concentrations of <10ng/ml category.
However, more than four times as many women with a previous sPTB had a qFFN concentration >200 ng/ml compared to those with prior cervical surgery ( Table 2 ).
The diagnostic accuracy of qFFN for predicting sPTB <30 weeks, <34 and <37 weeks' gestation in each group using pre-specified thresholds is shown in Tables 3, 4 and 5.
Using a qFFN concentration threshold of 10ng/ml gave a high negative predictive value for prediction of sPTB at all 3 gestational end-points in both groups. A qFFN concentration threshold of ≥200 ng/ml had high specificity for prediction of sPTB at all gestational end-points in both groups, although the optimal balance between sensitivity and specificity remains at 50ng/ml.
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The relative risk (RR) of sPTB at each gestational endpoint for each qFFN concentration is shown in Table 6 . In the cervical surgery group, the relative risk (RR) of sPTB <34 weeks for qFFN concentration threshold of 200g/ml was 21.8 (95% CI 5.5-86.8), almost triple the relative risk at the same threshold in the previous sPTB group; RR 6.7 (3.6-12.6).
Receiver operator characteristic (ROC) curves for prediction of sPTB < 30, < 34 and <37 weeks of gestation are shown in Figure 2 . ROC curves for prediction at each gestational end-point were comparable between the cervical surgery and previous sPTB groups, and the differences between the groups were not statistically Of the included cohort, 1,256 women had paired TVS CL measurements. Table 7 illustrates the proportion of women who delivered prematurely, stratified according to CL measurement, qFFN concentration and risk factor (cervical surgery or previous sPTB). Women with iatrogenic PTB were excluded. Of these women, 32/463 (7%) in the cervical surgery group, and 104/793 (13%) in the previous sPTB group had a CL <25mm.
Both FFN and CL were consistently strong and highly significant predictors of prematurity, as a test based on the combination, with little evidence that any test or M A N U S C R I P T 
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Comment
These data demonstrate that CVF qFFN measurement using the rapid bedside 10Q
analyser is a valuable and valid screening tool for assessing sPTB risk in asymptomatic primiparous women who have undergone prior cervical surgery, comparable to that in women with previous premature birth (in whom qFFN testing is well established). 8 Based on these results, a primiparous woman who has undergone previous cervical surgery and found to have a raised qFFN concentration of any value ≥10ng/ml has a greater than double the risk of delivering spontaneously before 34 weeks' gestation compared to a woman with a history of sPTB with the same qFFN test result, although absolute risks in this group remained lower. It is difficult to compare the absolute risks of cervical surgery and prior history given the different demographic of the populations. In spite of this the predictive ability remained good and therefore is likely to be generalizable.
Furthermore, the results confirm the increasingly recognised value of using quantitative, as opposed to qualitative fetal fibronectin; risk of sPTB is clearly related to the concentration of FFN in the CVF of women who have undergone previous cervical surgery. There may be value in using alternative risk thresholds at <10 ng/ml to define 'low risk' and >200 ng/ml to identify those women at higher risk,
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rather than the traditional 'positive/negative' threshold of 50 ng/ml. Although 50ng/ml is an appropriate single threshold, sensitivity and specificity are rarely equally weighted in clinical practice and quantification allows the clinician to tailor their decision-making.
A clinical tool that can be used to differentiate so-called 'high-risk' women is highly desirable, due to the likely outcome being a term birth even amongst women with previous poor obstetric histories. A test with a high sensitivity is desirable in these circumstances, when considering the balance of benefit and harm. For women with a previous preterm birth, a threshold of 10ng/ml has high sensitivity and specificity for prediction of spontaneous preterm birth. As such, a test with high sensitivity allows clinicians to reassure high-risk women with low qFFN concentration that they are likely to have a term birth. At all thresholds, sensitivity, specificity, positive and negative predictive values in both the cervical surgery group and previous sPTB are comparable; thus this test can be used with comparable accuracy in both asymptomatic high risk groups.
This is the largest study of qFFN to date in high-risk women with data obtained from a prospectively collected masked dataset. In terms of generalizability of results, the study population and sPTB rate was comparable to previously published high-risk studies. The study population was of varied ethnic origin and thus the test can be considered transferable to a broad high-risk population. The difference in ethnicities between the comparison groups may reflect the aetiology of the diseases being investigated, but there is no evidence to suggest the predictive M A N U S C R I P T
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Vandermolen 17 ability of the test is related to ethnicity. Although this generalizability is limited to nulliparous women, the mechanism in multiparous women is likely to be similar.
A limitation of the study design was that women involved with a history of pregnancy loss or early preterm birth were routinely offered cerclage if a short cervix was detected, a management compliant with UK Royal College of Obstetrician and
Gynaecologist guidelines (progesterone is not routinely prescribed). The use of cerclage may have influenced outcome (a likely 50% reduction in risk of sPTB <34
weeks' in these circumstances). A proportion of women in both groups underwent cervical cerclage during their pregnancy. As so few women received intervention (0.6% of women in the previous cervical surgery group and 2.4% of women in the previous PTB group) in both groups, this is unlikely to have had a major effect on the comparison between them. It is therefore possible that the predictive ability of the tests have been underestimated, as the cerclage may make a positive test a false positive result, and therefore the sensitivity could be even higher.
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It is well known that women with previous cervical surgery are at increased risk of preterm birth (RR 1.25-2.61 depending on the height of conization) [17] [18] [19] . There are several proposed mechanisms to explain their increased risk; structurally, the removal of cervical tissue may produce a mechanically weakened, shortened cervix which reduces its functioning during pregnancy, an effect that increases with increasing proportion of tissue removed. 20 It has also been suggested that previous cervical conisation leads to an impaired inflammatory response during pregnancy M A N U S C R I P T
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due to the loss of cervical glands, increasing the susceptibility to infection as well as altering the cervical flora to increase the risk of preterm premature rupture of the membranes (PPROM). 12, 19 In contrast, infection and inflammation are thought to play a major etiological role in sPTB without a history of cervical surgery, particularly at early gestations. 21 A recent paper by the RCOG Science Advisory Committee has stressed the need to determine antenatal interventions that could reduce the risk of sPTB for women who have had previous cervical surgery. Prediction of PTB using qFFN allows a clinician to reassure those women at low risk and direct them back to routine antenatal care, whilst identifying those at the highest risk, allowing for targeted interventions. These include providing antenatal corticosteroids and in utero transfer, as well as potentially guiding prophylactic intervention such as cervical cerclage or vaginal progesterone, but further trials are needed to confirm their efficacy in these groups.
CVF qFFN testing is a useful adjunct to CL measurement to accurately discriminate those women with a short cervix who were destined to deliver early; in the cervical surgery group, 3/23 (13%) of women who had a CL of <25mm and qFFN <10 ng/mL delivered spontaneously prior to 34 weeks' gestation, compared with 2/4 (50%) of those with a qFFN >200ng/mL. However, in contrast to TVS measurement of CL, qFFN can be performed with little training and depending on service provision, it may prove to be as useful and cheaper used as a stand-alone test. In the absence of CL measurement availability, a qFFN value of <10 ng/mL in a woman who is otherwise high risk having had previous cervical surgery will be immensely M A N U S C R I P T
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reassuring (<1.5% risk of sPTB <34 weeks). Currently NICE recommends consideration of prophylactic cervical cerclage for women with CL< 25 mm at [16] [17] [18] [19] [20] [21] [22] [23] [24] weeks gestation who have either previous sPTB or a history of cervical trauma.
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Given that many women with a short cervix do not deliver early, qFFN may be able to discriminate those women who may benefit from cerclage, and avoid overtreatment. This can be relied on as the risk of sPTB is lower than background risk if qFFN measurement is low and cervical length is long.
In the overall cohort study 9 , (which included both women with cervical surgery and women with previous pre-term birth, as well as uterine abnormalities) from which these women were selected, we demonstrated that the relative risk of sPTB increased as concentrations of qFFN increased and that thresholds of <10ng/ml and >200 ng/ml were particularly clinically relevant. The current study confirms that these observations are valid in women with previous cervical surgery alone.
Currently, women with previous cervical surgery are not routinely offered antenatal CVF screening for risk of PTB. 11 As this group has higher PTB rates than background rates, we believe screening is justified in this population. The implementation of qFFN, a clinically useful, low-risk, test has the potential to discriminate between women with a history of cervical surgery who no longer need intensive surveillance M A N U S C R I P T
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